ADM's BPL1™ Research Sets New Industry Standard for the Future of Probiotics

ADM's BPL1™ Research Sets New Industry Standard for the Future of Probiotics

ADM’s latest research into its proprietary probiotic strain Bifidobacterium animalis subsp. lactis (CECT 8145 BPL1™) is a world-first in elucidating a probiotic strain’s mechanism of action. This refers to the specific biochemical interaction through which research shows its potential role in impacting biomarkers related to weight management and metabolic health, with evidence of it setting a new milestone for the understanding of probiotics.

With this as evidence, ADM can support our partners in the dietary supplements and food and beverage sectors with the scientific understanding they need when considering current regulatory expectations for their claims and positioning, opening up new product development opportunities.

“The publication of this new research is the result of more than ten years of preclinical and clinical trials, demonstrating our commitment to using our scientific expertise to support innovations in the probiotic space”, said Daniel Ramón Vidal, ADM Vice President of Research and Development of the company’s Health & Wellness business.

“We’re excited to see how ADM can use this new evidence to support our partners in developing exciting new food, beverage and dietary supplement solutions.”

To find out more about the research, watch the video with Patricia Martorell Guerola, Marta Tortajada Serra and Daniel Ramón Vidal – the scientists leading the team behind the study. [1]


[1] Research into BPL1™ Bifidobacterium animalis subsp. lactis (CECT 8145) is a world-first